Table 2.
Likelihood of reporting first pregnancy and livebirth in survivors of childhood cancer compared with siblings
| Male survivors |
Female survivors |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pregnancy |
Livebirth |
Pregnancy |
Livebirth |
|||||||||
| n | HR (95% CI) | p value | n | HR (95% CI) | p value | n | HR (95% CI) | p value | n | HR (95% CI) | p value | |
| Siblings | 1066 | 1 | 961 | 1 | 1379 | 1 | 1240 | 1 | ||||
| Survivors, all | 1694 | 0·63 (0·58-0·68) | <0·0001 | 1425 | 0·63 (0·58-0·69) | <0·0001 | 2455 | 0·87 (0·81-0·94) | 0·00015 | 2028 | 0·82 (0·76-0·89) | <0·0001 |
| Ages 15-29 years during follow-up | 527 | 0·65 (0·59-0·71) | <0·0001 | 383 | 0·64 (0·58-0·71) | <0·0001 | 901 | 0·93 (0·86-1·01) | 0·069 | 681 | 0·87 (0·80-0·95) | 0·0025 |
| Ages 30-44 years during follow-up | 1167 | 0·56 (0·48-0·66) | <0·0001 | 1042 | 0·60 (0·51-0·70) | <0·0001 | 1554 | 0·60 (0·50-0·71) | <0·0001* | 1347 | 0·63 (0·53-0·76) | <0·0001* |
| Not exposed to any alkylating or similar drugs | 762 | 0·72 (0·66-0·80) | <0·0001 | 640 | 0·72 (0·65-0·80) | <0·0001 | 1083 | 0·90 (0·83-0·98) | 0·018 | 885 | 0·86 (0·79-0·94) | 0·0015 |
| Exposed to alkylating or similar drugs | 911 | 0·57 (0·52-0·63) | <0·0001† | 767 | 0·58 (0·52-0·64) | <0·0001* | 1345 | 0·86 (0·79-0·94) | 0·00040 | 1122 | 0·82 (0·75-0·90) | <0·0001 |
| Unknown alkylating drug status | 21 | .. | 18 | .. | 27 | .. | 21 | .. | ||||
Sex-specific models adjusted for race and ethnic origin, and year of birth. Age at first pregnancy or livebirth was not available for some survivors and was imputed (pregnancy, n=127; livebirth, n=84).
HR=hazard ratio.
*
For interaction with age, 30-44 years versus 15-29 years, p<0·0001 (pregnancy) and p=0·0016 (livebirth).
†
For exposure versus no exposure to any alkylating or similar drugs, difference in HRs, p=0·00058 (pregnancy) and p=0·0034 (livebirth).